text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 170787-99-2 | Product Number: E1356

Efaproxiral Sodium


Purity: >98.0%(T)(HPLC)
Synonyms:
  • RSR 13 Sodium
  • Sodium 2-[4-[2-[(3,5-Dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoate
  • 2-[4-[2-[(3,5-Dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic Acid Sodium Salt
Documents:
250MG
$149.00
13   10  

* Please contact our distributors or TCI to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.


Product Number E1356
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__2__0H__2__2NNaO__4 = 363.39 
Physical State (20 deg.C) Solid
Storage Temperature Frozen (-20°C)
Store Under Inert Gas Store under inert gas
Condition to Avoid Hygroscopic,Heat Sensitive
CAS RN 170787-99-2
Reaxys Registry Number 8959239
PubChem Substance ID 468591726
MDL Number

MFCD02093864

Specifications
Appearance White to Almost white powder to lump
Purity(HPLC) min. 98.0 area%
Purity(Nonaqueous Titration) min. 98.0 %(calcd.on anh.substance)
Melting point 240.0 to 244.0 °C
Water max. 13.0 %
Properties (reference)
GHS
Related Laws:
Transport Information:
H.S.code* 2924.29-000
*This code is applied to the products when TCI exports from Japan and not for import in your country.
Application
Efaproxiral Sodium: Developed as an Allosteric Modifier of Hemoglobin and a Radiation Sensitizer

Efaproxiral sodium (RSR 13 sodium), an analogue of the antilipemic agent bezafibrate [B3346], was developed as an allosteric modifier of hemoglobin1,2) and a radiation sensitizer.3) In the 2000s, efaproxiral sodium was tested in a clinical trial to increase the efficacy of certain chemotherapy agents which have reduced efficacy against hypoxic tumors, and can thus be made more effective by increased offloading of oxygen from hemoglobin-bound oxygen into the tumor tissues.4) But the clinical trial was dropped out in Phase III trials. In 2009, Efaproxiral was added to the World Anti-Doping Agency (WADA) list of Prohibited Substances as an artificially enhancer of the uptake, transport or delivery of oxygen.5) (The product is for research purpose only.)

References


Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.